Literature DB >> 15239136

Increased expression of inducible HSP70 in apoptotic cells is correlated with their efficacy for antitumor vaccine therapy.

Delphine Massé1, Frédéric Ebstein, Gwenola Bougras, Jean Harb, Khaled Meflah, Marc Grégoire.   

Abstract

Apoptosis is a physiologic process in normal development, tissue remodeling and cell turnover. This cell death is noninflammatory and nonimmunogenic, but when associated with a danger signal, it can activate the immune system. However, the capacity of apoptotic cells to activate the immune system is not clearly established, although dead tumor cells have been largely exploited as a source of TAA in cellular therapy against cancer. From these cellular preparations, contradictory results have been reported on the effect of apoptotic cells as an effective source of TAA and their immunologic properties. These conflicting data strongly suggest that the optimal preparation of apoptotic cells derived from tumor cells remains to be determined. In this work, we studied and compared the efficacy of antitumor immune responses derived from repeated injections using different preparations of apoptotic cells. We investigated the importance of HSP70 and TGF-beta expression in apoptotic cells used in the treatment of an established and nonimmunogenic rat carcinoma. UVB-mediated apoptosis did not affect TGF-beta expression in tumor cells, whereas HS treatment sharply downregulated it. Thus, downregulation of TGF-beta permits normal DC activation and maturation and the induction of tumor immunity. We conclude that HS followed by UVB irradiation is a superior source of tumor antigen for the treatment of established tumors. Future work will determine whether HS independently upregulates HSP70, thereby suppressing expression of active TGF-beta, or whether the 2 are linked via a still undefined mechanism. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15239136     DOI: 10.1002/ijc.20249

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk.

Authors:  F Cabillic; F Bouet-Toussaint; O Toutirais; N Rioux-Leclercq; P Fergelot; C Thomas de la Pintière; N Genetet; J-J Patard; V Catros-Quemener
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

2.  Photodynamic therapy of melanoma with new, structurally similar, NIR-absorbing ruthenium (II) complexes promotes tumor growth control via distinct hallmarks of immunogenic cell death.

Authors:  Prathyusha Konda; John A Roque Iii; Liubov M Lifshits; Angelita Alcos; Eissa Azzam; Ge Shi; Colin G Cameron; Sherri A McFarland; Shashi Gujar
Journal:  Am J Cancer Res       Date:  2022-01-15       Impact factor: 6.166

Review 3.  Interactions of tumor cells with dendritic cells: balancing immunity and tolerance.

Authors:  M V Dhodapkar; K M Dhodapkar; A K Palucka
Journal:  Cell Death Differ       Date:  2007-10-19       Impact factor: 15.828

Review 4.  Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

Authors:  Irena Adkins; Jitka Fucikova; Abhishek D Garg; Patrizia Agostinis; Radek Špíšek
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

5.  Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death.

Authors:  K Hayashi; F Nikolos; Y C Lee; A Jain; E Tsouko; H Gao; A Kasabyan; H E Leung; A Osipov; S Y Jung; A V Kurtova; K S Chan
Journal:  Nat Commun       Date:  2020-12-07       Impact factor: 14.919

Review 6.  Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer?

Authors:  Elisa Panzarini; Valentina Inguscio; Luciana Dini
Journal:  Biomed Res Int       Date:  2012-12-30       Impact factor: 3.411

7.  Molecular changes induced by the curcumin analogue D6 in human melanoma cells.

Authors:  Carla Rozzo; Manuela Fanciulli; Cristina Fraumene; Antonio Corrias; Tiziana Cubeddu; Ilaria Sassu; Sara Cossu; Valentina Nieddu; Grazia Galleri; Emanuela Azara; Maria Antonietta Dettori; Davide Fabbri; Giuseppe Palmieri; Marina Pisano
Journal:  Mol Cancer       Date:  2013-05-04       Impact factor: 27.401

Review 8.  MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.

Authors:  David Roulois; Marc Grégoire; Jean-François Fonteneau
Journal:  Biomed Res Int       Date:  2012-12-26       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.